UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 29, 2019

Heat Biologics, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-35994 (Commission File Number) 26-2844103

(IRS Employer Identification No.)

627 Davis Drive

Morrisville, North Carolina 27560 (Address of principal executive offices and zip code)

(919) 240-7133

(Registrant's telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0002 par value per share	HTBX	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

Heat Biologics, Inc. (the "Company") will be making corporate presentations over the next several weeks. In connection with the presentations, the Company intends to discuss the slide presentation attached as Exhibit 99.1 hereto, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is being filed as part of this Report.

Exhibit Number	Description
99.1	Presentation materials to be provided at Heat Biologics, Inc. presentations

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 29, 2019

HEAT BIOLOGICS, INC.

By: /s/ Jeffrey Wolf Name: Jeffrey Wolf Title: Chairman, President and Chief Executive Officer



Heat Biologics

NASDAQ: HTBX

CORPORATE PRESENTATION NOVEMBER 2019


Forward Looking Statements

This presentation includes statements that are, or may be deemed, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned discovery and development of drugs targeting cancer, the strength and breadth of our intellectual property, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to complete clinical trials and make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our ability to partner our product development, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation as a result of, among other factors, the factors referenced in the "Risk Factors" section of our Annual Report on Form 10-K/A for the year ended December 31, 2018, our quarterly reports on Form 10-Q for the subsequent quarters and our other subsequent filings with the Securities and Exchange Commission (collectively, our "SEC Filings"). In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation, except as required by law.

Snapshot of Heat Biologics (Nasdaq: HTBX)

- Biopharmaceutical company developing a suite of potential first-in-class immunotherapy products
- HS-110, an "off the shelf" cell-based immunotherapy product that has the potential to improve PD(L)-1 based therapy
 - Planning for registrational trial
 - Ongoing Phase 2 program demonstrates signals of efficacy in two treatment settings
 - Broad market potential in multiple oncology indications
 - Fully allogeneic product with low COGs
- Promising pipeline based on T-cell activation and co-stimulation
 - IND clearance by US FDA for HS-130, IND clearance for PTX-35 expected in Q2, 2020
 - Product pipeline offers additive clinical benefit when combined with anti-PD-(L)1 and other immunotherapies
- Experienced management team with proven track record advancing oncology drugs to the market



HS-110 Overview


- HS-110 is a Phase 2 cell-based immunotherapy administered in combination with PD-(L)1 therapies to improve clinical outcomes for NSCLC patients
 - Allogeneic cells with engineered gp96 to present 70+ different cancer testis antigens
 - Selectively activate CD8+ "killer" T cells
 - gp96 can up-regulate T-cell co-stimulation and maturation of antigen presenting cells (APCs)
- PD-(L)1 is approved for multiple cancers and combination approaches may enhance survival benefits

The combination of HS-110 and PD-(L)1 therapy may benefit patients that have progressed on prior PD-(L)1 therapy

References: Strbo et al 2013. Immunologic research; Strbo et al 2013. Journal of immunology; Yifei Wang et al. 2018. J Immunol; Heat Biologics Internal data; ‡ Shukuya & Carbone 2016. Journal of Thoracic Oncology, Vol.11 No.7: 976 - 988


PD(L)-1 Therapy is Approved for Multiple Cancers

Estimated Number of New Cases in 2018 Worldwide




Combination of HS-110 and PD(L)-1 therapy

- HS-110 is designed to overcome mechanisms of immune evasion, thereby having the potential to enable effective treatment with PD(L)-1
 - Target to be effective in patients that generally do not benefit from PD(L)-1 therapy



Clinical Support for HS-110 + Nivolumab MOA

"Turning COLD Tumors HOT"



Combination treatment drives "killer" CD8+ T-cells deep into tumors CD8+ TIL Infiltration Associated with Clinical Response

Data from Phase 1b/2 trial in advanced NSCLC patients treated by HS-110 + Nivolumab at 22L



HS-110 Clinical Data

A Phase 1b/2 Study of HS-110 in Combination with Multiple Treatment Regimens in Patients with NSCLC

This is a non-randomized, open-label study that assesses HS-110 in combination with nivolumab or pembrolizumab in four different patient populations with advanced NSCLC

HS-110 + Nivolumab

A. 2+ line Checkpoint Inhibitor (CPI) naïve patients

B. 2+ line patients that progressed following CPI treatment

HS-110 + Pembrolizumab ± Pemetrexed

C. 1st line patients achieving SD/PR prior to pembrolizumab maintenance therapy

D. 1st line patients achieving SD/PR prior to pembrolizumab + pemetrexed maintenance therapy

Primary Endpoints

- Cohort A & B: ORR
- Cohort C & D: PFS

Secondary Endpoints

OS, PFS, DCR, DOR

Exploratory Endpoints

- Baseline CD8+ TILs (Low defined as ≤ 10% stromal CD8+ TILs)
- PD-L1 expression (Negative defined as < 1% on tumor cells)
- Peripheral blood tumor mutation burden count
- (Low defined as < 10 mutations/ Mb) • ELISPOT cytokine analysis




A comparison with published literature in NSCLC patients treated with *nivolumab as a single agent*

	HS-110 + Nivolumab ^A 93% Non-squamous NSCLC 7% Squamous NSCLC	Nivolumab * Checkmate 57 Non-squamous NSCLC	Nivolumab ‡ Checkmate 17 Squamous NSCLC
ORR	20%	19%	20%
DCR	46%	44%	49%
Median PFS	1.9	2.3	3.5
Median OS	16.9 50% of pts still alive with median follow-up time of 17 months	12.2	9.2

^a Heat Biologics Cohort A interim results as of July 2019 data cut, n=46
 * Borghaei et al. 2015 New England Journal of Medicine. 373:1627-39, n=292
 ‡ Brahmer et al. 2015 New England Journal of Medicine. 373:123-135, n=135


Cohort A: CPI naïve pts treated by HS-110 + Nivolumab at 22L PFS by Injection Site Reaction (ISR)

Progression free survival (PFS) is significantly better in patients who experienced dermal injection site reaction, thus supporting the HS-110 mechanism of action



Cohort A: CPI noïve pts treated by HS-110 + Nivolumeb at >2L OS by Injection Site Reaction (ISR)

Overall survival (OS) is significantly better in patients who experienced dermal injection site reaction, thus supporting the HS-110 mechanism of action



- · Cohort A: Stage III or IV advanced NSCLC patients
- A comparison with published literature in NSCLC patients treated with <u>nivolumab as a single agent</u>

	<u>HS-110 + Nivolumab ∆</u>		<u>Nivolumab</u>		
	93% Non-squamous NSCLC and 7% Squamous NSCLC		Non-Squamous NSCLC Squa NSCLC		
(Months)	All (n=46)	ISR+ (n=26)	Checkmate 57* (n=292)	Checkmate 17‡ (n=135)	
Median PFS	1.9	6.1	2.3	3.5	
Median OS	16.9 50% of pts still alive with median follow-up time of 17 months	42.1	12.2	9.2	

^b Heat Biologics Cohort A interim results as of July 2019 data cut. Subgroup analysis by ISR was retrospective. ¹ ISR = injection site reaction. ² CD8+ TIL = CD8+ tumor infiltration lymphocytes at baseline (High > 10%, Low ≤ 10%). ³ PD-L1 (Positive ≥ 1%, Negative < 1%). NR = Not reached. As of last data cut-off in July, 2019. Median follow-up time = 14.4 months.</p>

HS-110 Clinical Data

A Phase 1b/2 Study of HS-110 in Combination with Multiple Treatment Regimens in Patients with NSCLC

This is a non-randomized, open-label study that assesses HS-110 in combination with nivolumab or pembrolizumab in four different patient populations with advanced NSCLC

HS-110 + Nivolumab

A. 2+ line Checkpoint Inhibitor (CPI) naïve patients

B. 2+ line patients that progressed following CPI treatment

HS-110 + Pembrolizumab ± Pemetrexed

C. 1st line patients achieving SD/PR prior to pembrolizumab maintenance therapy

D. 1st line patients achieving SD/PR prior to pembrolizumab + pemetrexed maintenance therapy

Primary Endpoints

- Cohort A & B: ORR
- Cohort C & D: PFS

Secondary Endpoints

OS, PFS, DCR, DOR


Exploratory Endpoints

- Baseline CD8+ TILs (Low defined as ≤ 10% stromal CD8+ TILs)
- PD-L1 expression (Negative defined as < 1% on tumor cells)
- Peripheral blood tumor mutation burden count
- (Low defined as < 10 mutations/ Mb) • ELISPOT cytokine analysis



Cohort B: CPI progressors treated by HS-110 + Nivolumab at ≥2L

Response and Disease Control



	HS-110 + Nivolumab [△]		Nivolumab †
	IRECIST	RECIST 1.1	RECIST 1.1
ORR	14% (8)	13% (7)	8.3% (10)
PR	14% (8)	13% (7)	8.3% (10)
SD	46% (26)	46% (26)	Not Available
Not Evaluable	7% (4)	7% (4)	Not Available
DCR	61% (34)	59% (33)	Not Available

^A Heat Biologics Cohort B as of July 2019 data cut; n=56. PR unconfirmed as study is actively ongoing at time of analyses. Per iRECIST, one patient achieved confirmed PR after initial radiographic PD.

+ Kazandjian et al 2017 Seminars in Oncology 44(2017)3-7. Retrospective analysis. Two of the 10 patients had unconfirmed responses. N=121.


Heat Biologics

15


As of July 2019 data cut

Cohort B: CPI progressors treated by HS-110 + Nivolumab at ≥2L

PFS by Injection Site Reaction (ISR)



OS by Injection Site Reaction (ISR)




mpared with Published Data

- Unresectable or metastatic NSCLC patients, heavily pretreated(63% with ≥ 2 lines of prior therapy)
- A comparison with published literature in NSCLC patients <u>after PD-(L)1 progression</u>

		Nivolumab fter CPI failure ∆		atment Option ≥ 3rd line after CPI fail	
(Months)	All (n=56)	ISR+ (n=39)	Gemcitabine † (n=27)	Docetaxel [†] (n=25)	Chemotherap y ‡ (n=28)
Median PFS	3.2	3.7	2.8	2.7	4.7
Median OS	11.8	12.0	7.5	6.8	9.0

^a Heat Biologics Cohort B as of July 2019 data cut estimate with 70% of the patients still alive. ORR and DCR unconfirmed as study is actively ongoing at time of analyses. ORR performed locally by study Investigators using RECIST 1.1. [†] Single agent chemotherapy, Constatini et al 2018 ERJ Open Research ‡ Schvartsman et al 2017 Lung Cancer

Favorable Safety Profile to Date



*Represents the only patient of 150+ patients dosed who discontinued treatment for a HS-110 related adverse event


- Over 1,000 doses administered to 150+ patients
- Only one patient ended treatment due to an HS-110 related non-serious adverse reaction *
- No treatment-related serious adverse reactions
- No increase in immune-related adverse events compared to single-agent checkpoint inhibitors

No additive toxicities to standard of care



As of last data cut in 2019

Product Pipeline




HS-130 Overview

• HS-130 is the first allogeneic, off-the-shelf, cell therapy approach utilizing OX40-mediated co-stimulation to enhance activation of dormant immune signal

- Leverage HS-110 clinical experience and manufacturing know-how
- Addition of OX40L fusion protein to extend and expand T cell memory
- IND clearance by US FDA. Phase 1 expected to commence in Q4/2019
- Mechanism of Action offers broad market potential
- Heat Biologics has worldwide rights

Product Pipeline



PTX-35 Overview

- Potential first-in-class T cell co-stimulator targeting TNFRSF25, with preferential specificity to generate "memory" CD8+ T cells
 - FDA clearance of PTX-35 IND expected in Q2, 2020
- Broad market potential
 - Efficacy demonstrated in multiple preclinical *in vivo* colon, lung and breast cancer models
- Synergistic combination with immunotherapies including HS-110 and CPIs

- Awarded a \$15.2M grant to fund 70 pt. clinical trial
- Heat Biologics has worldwide rights



24

Heat Biologics

NASDAQ: HTBX

APPENDIX




25

HS-110


MOA AND PRECLINICAL DATA

PD(L)-1 Therapy is Approved for Multiple Cancers



Heat's Combination Platforms

Unlocking the Body's Natural Defenses with a Broad Range of Combination Therapies



Introducing gp96 – Its dual role

The Immune System's "Swiss Army Knife"*



"Molecular Warning System"

- A natural biological process to deliver proteins (antigens) & gp96 to our immune system
- Gp96 "chaperones" newly-created proteins to the cell membrane where they are released and embedded
- Gp96 chaperoned proteins are only naturally released via necrosis
- Gp96, when present outside the cell, alerts the immune system and then becomes one of the most powerful adjuvants that show exclusive specificity to CD8+ ("killer") T-cells

Heat Biologics

*Schild, H. & Rammensee, H. Gp-96 – The Immune System's Swiss Army Knife. Nature Immunology 2, 100-101 (2000)


Heat's T Cell Activation Platform - ImPACT®

"Severing the Leash


Heat Biologics ImPACT[®] technology reprograms cancer cells to continuously secrete their own antigens

ImpACT* technology genetically modifies tumor cells by "severing the leash" that binds the gp96 to the endoplasmic reticulum, and replacing it with a secretory sequence that pumps gp96 out of the cell
 Mimics necrotic cell death by enabling fully-allogeneic "off-the-shelf" living cancer cells to "pump-out" their own antigens along with their gp96 to the cell

HS-110 Mechanism of Action



HS-110 Mechanism of Action




- HS-110 is derived from a lung adenocarcinoma cell line transfected with gp96-lg, where the gp96 KDEL ER retention sequence is replaced by IgG1 Fc
- gp96-lg acts as a chaperone protein for tumor associated antigens and is recognized by CD91 on APCs; resulting in cross-presentation of antigen to MHC I for the selection of antigen-specific CD8 cells
- gp96-Ig also binds to TLRs 2 and 4 leading to upregulation of co-stimulatory molecules, which include MHC II and secretion of cytokines and chemokines




HS-110: Heat's Proprietary Cell Line

Heat's unique cell-secreted gp96 firstly activates dendritic cells via TLR signaling and subsequently CD8+ T cells via antigen cross presentation



32

ImPACT[®] "Off-the-shelf" Manufacturing





Key Data Summary

- Response rate by RECIST 1.1
 - Objective response rate (ORR) was 13%
 - Disease control rate (DCR) was 59%
- Median overall survival (OS) was estimated at 11.8 months with 70% of patients still alive
- Median progression free survival (mPFS) was 3.2 months
- · Patients who experienced an ISR vs. those who did not:
 - Improved PFS (HR = 0.40, p = 0.0068)
 - Improved OS (HR = 0.16, p = 0.0005)
- The effect of HS-110 in combination with nivolumab is not dependent on PD-L1 expression

Heat Biologics

34

Combination of HS-110 and nivolumab was well tolerated by patients

As of July 2019 data cut



35

PTX-35

PRECLINICAL DATA

TNFRSF25

An Emerging Target for T-cell Co-stimulation

Target	Companies	Co-stimulator Combinations		
	Pfizer, ISA Pharma,	Phase 1/2		
4-1BB	Gilead, Bristol Myers,	Combinations: Chemotherapy, epigenetic modulator, CD20 mAb, HPV vaccine,		
4 100	Inhibrx, Immatics, Pieris,			
	NCI	w/ HER-2, two co-stimulators (w/ OX40)		
MedImmune, GSK, Incyte, Phase 1/2				
OX40	Genentech, Pfizer,	OX-40 prior to surgery. Other combinations: PD-1, PD-L1, CTLA4, axitinib, 41BB,		
01110	AbbVie, Bristol Myers,	smoothened inhibitor Anti-CD33, azacitidine, TLRs, bi-specifics of OX40 and		
	Alligator Bio	CTLA-4		
	Novartis, Incyte-Agenus,	Phase 1		
GITR	MedImmune, Leap	Combinations: PD-1, Fc disabled co-stimulation, hexameric GITR ligand, IDO		
	Therapeutics, BMS, OncoMed	inhibitor, CTLA-4, GITR ligand-fusion		
		PL		
CD27	Celldex-BMS, Merck-	Phase 1/2		
Aduro	Aduro	Combinations: PD-1/L-1, sunitinib, CD20, melanoma vaccine, TL3 agonist		
ICOS	Celgene-Jounce, GSK	Phase 1/2		
1005	cengene rounce, ont	Combinations: PD-1, CTLA4, docetaxel		
TNFRSF25	Heat (under Pelican)	FDA clearance of PTX-35 IND expected in Q2, 2020 in advanced solid tumors		


Pelican is the only company with a disclosed program targeting TNFRSF25

TNFRSF25 as a Novel I/O Combination Target

- TNFRSF25 is one of the most recently discovered T cell costimulator, and is a rapidly emerging target
- Pelican is the only company developing TNFRSF25 agonist antibodies for I/O

"Although TNFRSF25 is chromosomally localized with 4-1BB, OX40, GITR and CD27, sequence analysis suggests that TNFRSF25 is relatively divergent or perhaps ancestral... Thus we might expect that therapeutics directed against this pathway will have unique activity."

Comment from Gordon Freeman et al




TNFRSF25: Why So Complicated?

TNFRSF25's evolutionary origin

One molecule - three types of T-cells Potentially a mechanism that preserves needed tissue and Expand but delay activation of existing Treg Expand activated CD8+ friendly bacteria during an immune response nhibits Tconv to iTreg **-X**► CD4 Example: gut invasion occurs in the context of friendly microbiome bacteria. How does the body protect what is needed while weeding out invaders?


TNFRSF25 is preferentially expressed on CD8+ and CD4+ T-cells T-cells

compared to other T-cell co-stimulators



- · Co-stimulation occurs only in the context of TCR recognition of antigen
- Drives the development of antigen-specific CD8+ T-cells

(mimics TL1A, the specific ligand of TNFRSF25)




Compared to agonists OX40, GITR, 4-1BB:


- TNFRSF25 shows superior activity in stimulating memory CD8+ cells in mice
- TNFRSF25 agonism plus ImPACT results in improved survival in mouse melanoma models

Preferential CD8+ T-cell Induction with TNFRSF25 in Mice

Pre-clinical studies with murine agonist antibody shows TNFRSF25 preferentially 'boosts' CD8+ T-cells, whereas OX40 is preferential to CD4+ T-cells



TNFRSF25 agonist + ImPACT Significantly Increases Survival in Mice Established (nine-day) B16-F10 melanoma mouse model





44

Heat Biologics

NASDAQ: HTBX

CORPORATE PRESENTATION NOVEMBER 2019